RE:Message to Shareholders, November 2022New entrant for Aggrastat allowed into the Market this month and completely off patent in Q1. Zypitimag sales not growing all that fast to replace and Marley Drugs under MPH Management has had decreasing sales since being aquired. Wait for possible devaluation at year end. enjoy a quarter or two.....then Aggrastat sales will plummet...Note that all improvement is cost cutting (actually key staff left) and a change in Amortization of Zypitimag. Company can not grow sales materially as shown quarter over quarter. PHD in stupid running the Company. Need to get Zypitimag over 1 Million a quarter or cash flow will rapidly turns south end of Q1